A β-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis

PLoS ONE

Volumn 3, Issue 9, 2008, Pages

  Melzer, Nico ^a   Meuth, Sven G ^a   Torres Salazar, Delany ^b,c   Bittner, Stefan ^a   Zozulya, Alia L ^a   Weidenfeller, Christian ^a   Kotsiari, Alexandra ^b   Stangel, Martin ^b   Fahlke, Christoph ^b   Wiendl, Heinz ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; DIHYDROKAINIC ACID; EXCITATORY AMINO ACID TRANSPORTER 2; GAMMA INTERFERON; GLUTAMIC ACID; INTERLEUKIN 17; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; ANTIINFECTIVE AGENT; BETA LACTAM; GLUTAMATE TRANSPORTER;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; BRAIN DAMAGE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG TARGETING; ENCEPHALITIS; EXCITOTOXICITY; FEMALE; HOMEOSTASIS; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CENTRAL NERVOUS SYSTEM; CYTOLOGY; DRUG EFFECT; GLIA; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY; RAT;

ANIMALIA; MAMMALIA; MURINAE;

AMINO ACID TRANSPORT SYSTEM X-AG; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFTRIAXONE; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; NEUROGLIA; RATS;

EID: 52149087280     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003149     Document Type: Article

References (54)

1. Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 354: 942-955.
2. Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23: 683-747.
3. Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971.
4. Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14: 271-278.
5. Werner P, Pitt D, Raine CS (2001) Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50: 169-180.
6. Newcombe J, Uddin A, Dove R, Patel B, Turski L, et al. (2008) Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 18: 52-61.
7. Piani D, Frei K, Do KQ, Cuenod M, Fontana A (1991) Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci Lett 133: 159-162.
8. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, et al. (2006) Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 281: 21362-21368.
9. Garg SK, Banerjee R, Kipnis J (2008) Neuroprotective Immunity: T Cell-Derived Glutamate Endows Astrocytes with a Neuroprotective Phenotype. J Immunol 180: 3866-3873.
10. Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6: 67-70.
11. Smith T, Groom A, Zhu B, Turski L (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6: 62-66.
12. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, et al. (2008) Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest.
13. Kleinschnitz C, Meuth SG, Kieseier BC, Wiendl H (2007) Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets 7: 35-63.
14. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, et al. (2005) Betalactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73-77.
15. Herrero-Herranz E, Pardo LA, Gold R, Linker RA (2008) Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: Implications for multiple sclerosis. Neurobiol Dis.
16. Chandrasekar PH, Rolston KV, Smith BR, LeFrock JL (1984) Diffusion of ceftriaxone into the cerebrospinal fluid of adults. J Antimicrob Chemother 14: 427-430.
17. Nau R, Prange HW, Muth P, Mahr G, Menck S, et al. (1993) Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother 37: 1518-1524.
18. Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, et al. (1994) Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 14: 5559-5569.
19. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65: 1-105.
20. Otis TS, Kavanaugh MP (2000) Isolation of current components and partial reaction cycles in the glial glutamate transporter EAAT2. J Neurosci 20: 2749-2757.
21. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, et al. (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276: 1699-1702.
22. Levy LM, Warr O, Attwell D (1998) Stoichiometry of the glial glutamate transporter GLT-1 expressed inducibly in a Chinese hamster ovary cell line selected for low endogenous Na+-dependent glutamate uptake. J Neurosci 18: 9620-9628.
23. Zerangue N, Kavanaugh MP (1996) Flux coupling in a neuronal glutamate transporter. Nature 383: 634-637.
24. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125: 1297-1308.
25. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, et al. (2003) Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 197: 1073-1081.
26. Chen W, Aoki C, Mahadomrongkul V, Gruber CE, Wang GJ, et al. (2002) Expression of a variant form of the glutamate transporter GLT1 in neuronal cultures and in neurons and astrocytes in the rat brain. J Neurosci 22: 2142-2152.
27. Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, et al. (2008) Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem.
28. Tian G, Lai L, Guo H, Lin Y, Butchbach ME, et al. (2007) Translational control of glial glutamate transporter EAAT2 expression. J Biol Chem 282: 1727-1737.
29. Canton T, Bohme GA, Boireau A, Bordier F, Mignani S, et al. (2001) RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J Pharmacol Exp Ther 299: 314-322.
30. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW (1993) Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 90: 6591-6595.
31. Rothstein JD, Kuncl RW (1995) Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 65: 643-651.
32. Spalloni A, Albo F, Ferrari F, Mercuri N, Bernardi G, et al. (2004) Cu/ Znsuperoxide dismutase (GLY93-.ALA) mutation alters AMPA receptor subunit expression and function and potentiates kainate-mediated toxicity in motor neurons in culture. Neurobiol Dis 15: 340-350.
33. Chu K, Lee ST, Sinn DI, Ko SY, Kim EH, et al. (2007) Pharmacological Induction of Ischemic Tolerance by Glutamate Transporter-1 (EAAT2) Upregulation. Stroke 38: 177-182.
34. Lipski J, Wan CK, Bai JZ, Pi R, Li D, et al. (2007) Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience 146: 617-629.
35. Ouyang YB, Voloboueva LA, Xu LJ, Giffard RG (2007) Selective dysfunction of hippocampal CA1 astrocytes contributes to delayed neuronal damage after transient forebrain ischemia. J Neurosci 27: 4253-4260.
36. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, et al. (2008) Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience.
37. Furuta A, Rothstein JD, Martin LJ (1997) Glutamate transporter protein subtypes are expressed differentially during rat CNS development. J Neurosci 17: 8363-8375.
38. Weiss ME, Adkinson NF (1988) Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 18: 515-540.
39. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, et al. (1998) HLA-restricted, processing-and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 102: 1591-1598.
40. Padovan E, von Greyerz S, Pichler WJ, Weltzien HU (1999) Antigen-dependent and -independent IFN-gamma modulation by penicillins. J Immunol 162: 1171-1177.
41. Brooks BM, Flanagan BF, Thomas AL, Coleman JW (2001) Penicillin conjugates to interferon-gamma and reduces its activity: a novel drug-cytokine interaction. Biochem Biophys Res Commun 288: 1175-1181.
42. Brooks BM, Hart CA, Coleman JW (2005) Differential effects of beta-lactams on human IFN-gamma activity. J Antimicrob Chemother 56: 1122-1125.
43. Brooks BM, Thomas AL, Coleman JW (2003) Benzylpenicillin differentially conjugates to IFN-gamma, TNF-alpha, IL-1beta, IL-4 and IL-13 but selectively reduces IFN-gamma activity. Clin Exp Immunol 131: 268-274.
44. Meuth SG, Simon OJ, Grimm A, Melzer N, Herrmann AM, et al. (2008) CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol 194: 62-69.
45. Becher B, Bechmann I, Greter M (2006) Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med 84: 532-543.
46. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, et al. (2005) Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11: 328-334.
47. Heppner FL, Greter M, Marino D, Falsig J, Raivich G, et al. (2005) Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 11: 146-152.
48. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD (2005) Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11: 335-339.
49. McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890-902.
50. Heine S, Ebnet J, Maysami S, Stangel M (2006) Effects of interferon-beta on oligodendroglial cells. J Neuroimmunol 177: 173-180.
51. Melzer N, Biela A, Fahlke C (2003) Glutamate modifies ion conduction and voltage-dependent gating of excitatory amino acid transporter-associated anion channels. J Biol Chem 278: 50112-50119.
52. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92.
53. Ortler S, Leder C, Mittelbronn M, Zozulya AL, Knolle PA, et al. (2008) B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. Eur J Immunol.
54. Dixon W, Massey F (1969) Introduction to statistical analysis. New York: McGraw-Hill.